Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab plus teniposide versus bevacizumab for recurrent glioblastoma
ChiCTR2600135234Phase 2Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Nov 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab and teniposide in glioblastoma (GBM) (2 arms), sponsored by Tangdu Hospital. Primary endpoint: Overall survival. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
bevacizumabteniposide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2600135234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135234.